Cargando…
A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging
PURPOSE: Prediction of mortality risk is important in the management of chronic heart failure (CHF). The aim of this study was to create a prediction model for 5-year cardiac death including assessment of cardiac sympathetic innervation using data from a multicenter cohort study in Japan. METHODS: T...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122818/ https://www.ncbi.nlm.nih.gov/pubmed/24663289 http://dx.doi.org/10.1007/s00259-014-2759-x |
_version_ | 1782329395891929088 |
---|---|
author | Nakajima, Kenichi Nakata, Tomoaki Yamada, Takahisa Yamashina, Shohei Momose, Mitsuru Kasama, Shu Matsui, Toshiki Matsuo, Shinro Travin, Mark I. Jacobson, Arnold F. |
author_facet | Nakajima, Kenichi Nakata, Tomoaki Yamada, Takahisa Yamashina, Shohei Momose, Mitsuru Kasama, Shu Matsui, Toshiki Matsuo, Shinro Travin, Mark I. Jacobson, Arnold F. |
author_sort | Nakajima, Kenichi |
collection | PubMed |
description | PURPOSE: Prediction of mortality risk is important in the management of chronic heart failure (CHF). The aim of this study was to create a prediction model for 5-year cardiac death including assessment of cardiac sympathetic innervation using data from a multicenter cohort study in Japan. METHODS: The original pooled database consisted of cohort studies from six sites in Japan. A total of 933 CHF patients who underwent (123)I-metaiodobenzylguanidine (MIBG) imaging and whose 5-year outcomes were known were selected from this database. The late MIBG heart-to-mediastinum ratio (HMR) was used for quantification of cardiac uptake. Cox proportional hazard and logistic regression analyses were used to select appropriate variables for predicting 5-year cardiac mortality. The formula for predicting 5-year mortality was created using a logistic regression model. RESULTS: During the 5-year follow-up, 205 patients (22 %) died of a cardiac event including heart failure death, sudden cardiac death and fatal acute myocardial infarction (64 %, 30 % and 6 %, respectively). Multivariate logistic analysis selected four parameters, including New York Heart Association (NYHA) functional class, age, gender and left ventricular ejection fraction, without HMR (model 1) and five parameters with the addition of HMR (model 2). The net reclassification improvement analysis for all subjects was 13.8 % (p < 0.0001) by including HMR and its inclusion was most effective in the downward reclassification of low-risk patients. Nomograms for predicting 5-year cardiac mortality were created from the five-parameter regression model. CONCLUSION: Cardiac MIBG imaging had a significant additive value for predicting cardiac mortality. The prediction formula and nomograms can be used for risk stratifying in patients with CHF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-014-2759-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4122818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-41228182014-08-08 A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging Nakajima, Kenichi Nakata, Tomoaki Yamada, Takahisa Yamashina, Shohei Momose, Mitsuru Kasama, Shu Matsui, Toshiki Matsuo, Shinro Travin, Mark I. Jacobson, Arnold F. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Prediction of mortality risk is important in the management of chronic heart failure (CHF). The aim of this study was to create a prediction model for 5-year cardiac death including assessment of cardiac sympathetic innervation using data from a multicenter cohort study in Japan. METHODS: The original pooled database consisted of cohort studies from six sites in Japan. A total of 933 CHF patients who underwent (123)I-metaiodobenzylguanidine (MIBG) imaging and whose 5-year outcomes were known were selected from this database. The late MIBG heart-to-mediastinum ratio (HMR) was used for quantification of cardiac uptake. Cox proportional hazard and logistic regression analyses were used to select appropriate variables for predicting 5-year cardiac mortality. The formula for predicting 5-year mortality was created using a logistic regression model. RESULTS: During the 5-year follow-up, 205 patients (22 %) died of a cardiac event including heart failure death, sudden cardiac death and fatal acute myocardial infarction (64 %, 30 % and 6 %, respectively). Multivariate logistic analysis selected four parameters, including New York Heart Association (NYHA) functional class, age, gender and left ventricular ejection fraction, without HMR (model 1) and five parameters with the addition of HMR (model 2). The net reclassification improvement analysis for all subjects was 13.8 % (p < 0.0001) by including HMR and its inclusion was most effective in the downward reclassification of low-risk patients. Nomograms for predicting 5-year cardiac mortality were created from the five-parameter regression model. CONCLUSION: Cardiac MIBG imaging had a significant additive value for predicting cardiac mortality. The prediction formula and nomograms can be used for risk stratifying in patients with CHF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-014-2759-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2014-03-25 2014 /pmc/articles/PMC4122818/ /pubmed/24663289 http://dx.doi.org/10.1007/s00259-014-2759-x Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article Nakajima, Kenichi Nakata, Tomoaki Yamada, Takahisa Yamashina, Shohei Momose, Mitsuru Kasama, Shu Matsui, Toshiki Matsuo, Shinro Travin, Mark I. Jacobson, Arnold F. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging |
title | A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging |
title_full | A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging |
title_fullStr | A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging |
title_full_unstemmed | A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging |
title_short | A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging |
title_sort | prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)i-metaiodobenzylguanidine imaging |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122818/ https://www.ncbi.nlm.nih.gov/pubmed/24663289 http://dx.doi.org/10.1007/s00259-014-2759-x |
work_keys_str_mv | AT nakajimakenichi apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT nakatatomoaki apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT yamadatakahisa apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT yamashinashohei apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT momosemitsuru apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT kasamashu apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT matsuitoshiki apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT matsuoshinro apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT travinmarki apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT jacobsonarnoldf apredictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT nakajimakenichi predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT nakatatomoaki predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT yamadatakahisa predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT yamashinashohei predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT momosemitsuru predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT kasamashu predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT matsuitoshiki predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT matsuoshinro predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT travinmarki predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging AT jacobsonarnoldf predictionmodelfor5yearcardiacmortalityinpatientswithchronicheartfailureusing123imetaiodobenzylguanidineimaging |